Back to top
more

Rapt Therapeutics (RAPT)

(Real Time Quote from BATS)

$7.74 USD

7.74
31,889

-0.19 (-2.40%)

Updated Apr 19, 2024 09:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?

by Zacks Equity Research

RAPT Therapeutics (RAPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron

by Zacks Equity Research

Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron are included in this Analyst Blog.

Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates

by Zacks Equity Research

Earnings from Moderna (MRNA) and pipeline update from RAPT are in focus in the biotech sector.

How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 90.48%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 90.5% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -1.02% and 11.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Rapt Therapeutics (RAPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Rapt Therapeutics (RAPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Factors to Note Ahead of Hewlett Packard (HPE) Q1 Earnings

by Zacks Equity Research

Hewlett Packard's (HPE) fiscal first-quarter results are likely to reflect gains from growing demand for its cloud services amid the ongoing digital transformation trend.

Wall Street Analysts See a 57.57% Upside in Rapt Therapeutics (RAPT): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 57.6% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Factors to Note Ahead of Zscaler's (ZS) Q2 Earnings Release

by Zacks Equity Research

The increased demand for security and networking products amid the ongoing hybrid work environment and digitization process is likely to have aided Zscaler's (ZS) second-quarter performance.

What Makes Rapt Therapeutics (RAPT) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Rapt Therapeutics (RAPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -5.56% and 66.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Emergent Biosolutions (EBS) Moves 12.5% Higher: Will This Strength Last?

by Zacks Equity Research

Emergent Biosolutions (EBS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 66.77%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Rapt Therapeutics (RAPT) points to a 66.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's Why 'Trend' Investors Would Love Betting on Rapt Therapeutics (RAPT)

by Zacks Equity Research

Rapt Therapeutics (RAPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Does Rapt Therapeutics (RAPT) Have the Potential to Rally 122% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Rapt Therapeutics (RAPT) points to a 122.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Why RAPT Therapeutics (RAPT) Stock Might be a Great Pick

by Zacks Equity Research

RAPT Therapeutics (RAPT) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 116%

by Zacks Equity Research

The consensus price target hints at an 115.5% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of 3.08% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -197.29% and 33.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Certara, Inc. (CERT) Q3 Earnings Miss Estimates

by Zacks Equity Research

Certara, Inc. (CERT) delivered earnings and revenue surprises of -9.09% and 2.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here's Why Rapt Therapeutics (RAPT) Looks Ripe for Bottom Fishing

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Rapt Therapeutics (RAPT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 74%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 73.7% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Rapt Therapeutics (RAPT) Climb 59% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 58.9% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Rapt Therapeutics (RAPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of 17.33% and 121.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?